AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer | MicrobiomeTrials
AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-06-01Est. Completion: 2027-06-01
Enrollment target: 46 participants
Locations
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Other microbiome trials you might be interested in